Regarding targeted therapy, in a phase II clinical trial investigating apatinib, an innovative angiogenesis inhibitor targeting vascular endothelial growth factor receptor-2, as a secondary treatment for R/M cervical carcinoma, researchers observed a median PFS of 5.13 months and an OS of 12.3 months (46). Here, KDR is linked to cervical carcinoma.